Cenix BioScience, a discovery-stage contract research provider and technology developer, has signed a research agreement with SYGNIS Bioscience, a pharmaceutical company dedicated to developing innovative therapies for the treatment of disorders of the central nervous system.

Under the research agreement's first assignment to advance the SYGNIS
KIBRA project, Cenix will apply its long-standing expertise in combining
high content screening with gene silencing analyses in cultured human cells, to establish and optimize multi-parametric microscopy-based assays using the Definiens XD image analysis system.

Using such assays, Cenix will conduct target validation to prioritize
novel therapeutic drug target candidates, thereby accelerating and enriching the SYGNIS drug development pipeline.
 
"We are delighted to enter into this new relationship with SYGNIS," noted Dr. Christophe Echeverri, CEO/CSO of Cenix. "This project, and the many others like it now ongoing here and throughout the industry, continue to confirm the unparalleled power of RNAi-based experimentation for not only discovering but also validating and de-risking new candidate drug targets."